Shots: Roche has initiated the P-III program for fenebrutinib (BTK inhibitor) in RMS and PPMS which include two identical P-III trials in RMS (FENhance 1& FENhance 2) and one P-III […]readmore
Tags : Clinical Program
Shots: The first patient has been treated as a part of the global clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe COVID-19. The P-II/III clinical program has initiated […]readmore
Shots: The P-II/III study will assess the safety & efficacy Kevzara + supportive care vs PBO + supportive care in ~400 patients in a ratio (2:2:1) hospitalized with serious complications […]readmore
Shots: Astellas to initiate global BRIGHT SKY program which includes three P-III studies (SKYLIGHT 1, SKYLIGHT 2 and SKYLIGHT 4) and will assess fezolinetant (30/45mg, qd) in postmenopausal women with […]readmore